. Author manuscript; available in PMC: 2015 Apr 8.

Published in final edited form as: Am J Ophthalmol. 2014 Aug 1;158(5):1071–1078. doi: 10.1016/j.ajo.2014.07.036

Table.

Characteristics of Patients and Baseline Parameters of Wet Age-Related Macular Degeneration Groups, With or Without Omega-3 Supplementation, and the Control Group

Parameter	Wet AMD			Control (Group 4)^a	P Value
Parameter	Anti-VEGF Plus Omega-3 (Group 1)	Anti-VEGF (Group 2)	Anti-VEGF Naïve (Group 3)	Control (Group 4)^a	P Value
Age (y)	79.6 ± 1.81	79.00 ± 1.98	83.38 ± 2.32	68.25 ± 3.56	.0099^b
No. female (%)	5 (56)	3 (50)	2 (29)	7 (86)	.144^c
Visual acuity^d	0.61 ± 0.14	0.84 ± 0.17	0.78 ± 0.15	n.a.	.6606^b
No. of previous injections	8 ± 1.19	6 ± 1.51	n.a.	n.a.	.5287^b
Time from last injection (wks)	8 ± 0.40	8 ± 0.36	n.a.	n.a.	.9999^b

No. of patients 9 6 7 8 AMD = age-related macular degeneration; n.a. = not applicable; VEGF = vascular endothelial growth factor.

Epiretinal membrane and macular hole patients.

Student t test.

Fisher exact probability test.

Logarithm of the minimal angle of resolution units.